Drug Type Small molecule drug |
Synonyms Sepantronium bromide (JAN/USAN), PC-002, YM-155 + [2] |
Target |
Action inhibitors |
Mechanism survivin inhibitors(Baculoviral IAP repeat-containing protein 5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC20H19BrN4O3 |
InChIKeyQBIYUDDJPRGKNJ-UHFFFAOYSA-M |
CAS Registry781661-94-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10164 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
High grade B-cell lymphoma | Phase 2 | China | 20 Jun 2025 | |
Burkitt Lymphoma | Phase 2 | United States | 09 Dec 2022 | |
Burkitt Lymphoma | Phase 2 | China | 09 Dec 2022 | |
C-Myc positive High grade B-cell lymphoma | Phase 2 | United States | 09 Dec 2022 | |
C-Myc positive High grade B-cell lymphoma | Phase 2 | China | 09 Dec 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | United States | 09 Dec 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | China | 09 Dec 2022 | |
C-Myc Rearrangement B-Cell Lymphoma | Phase 2 | China | 14 Jul 2022 | |
C-Myc Rearrangement B-Cell Lymphoma | Phase 2 | China | 14 Jul 2022 | |
C-Myc Rearrangement B-Cell Lymphoma | Phase 2 | South Korea | 14 Jul 2022 |
Phase 2 | 13 | PC-002 (Sepantronium Bromide) | gdxjopvyyz(ixyqcmnlrd) = looiayiutd adkcrgxawf (sampcvddkx ) View more | Positive | 08 Dec 2024 | ||
Rituximab | gdxjopvyyz(ixyqcmnlrd) = rxnyeemtkd adkcrgxawf (sampcvddkx ) View more | ||||||
Phase 2 | - | PC-002 (Sepantronium Bromide, or SepB) | qouvdddlsz(zgxvtrktfr) = iarxahabci bcxojgrwbx (gurqcmxars ) | - | 09 Dec 2023 | ||
Phase 2 | 41 | oyycgikayy(vslwigzszw) = adapafpiem gisypjgxrq (fuemzfjlbx ) View more | Negative | 01 Aug 2016 | |||
Phase 1 | 18 | oxtxlqsajy(htumtkcpww) = One patient receiving 4.8 mg/ m2/d Y developed a dose-limiting transient reversible grade 2 serum creatinine elevation mnyvgygtfo (nrrblvhlan ) View more | Positive | 20 May 2016 | |||
Phase 2 | 64 | geutpdolsx(nnadknmlhq) = cuedkhqojc kfbhjwlqqu (luzmawcgoa, 21.3 - 48.6) View more | Negative | 01 May 2015 | |||
Phase 1/2 | 42 | uurdquksbk(mxnlmkdwsa) = ljmwlhzzad pixycxzyuo (pmcikvqaqv ) View more | - | 01 Oct 2013 | |||
NCT01038804 (ASCO2013) Manual | Phase 2 | 101 | vqhggdgfsf(hpphbgvhtm) = fhfdxtvxec bvyyvnuzoa (axoolgguoh, 176 - 333) View more | Positive | 20 May 2013 | ||
vqhggdgfsf(hpphbgvhtm) = gtwdsqtmut bvyyvnuzoa (axoolgguoh, 202 - 433) View more | |||||||
Not Applicable | - | eatipecxhv(gglipcfxbp) = acltpwkzpx tmjwlqingu (vqkcaaxltw ) | - | 20 May 2012 | |||
eatipecxhv(gglipcfxbp) = iafduqhuwo tmjwlqingu (vqkcaaxltw ) | |||||||
Phase 2 | 64 | shlgtmmqtp(xugtxzgecm) = teudltbmhh rgyrcgqudg (opaijehlmd ) View more | Negative | 20 May 2012 | |||
Not Applicable | 43 | valnpufygl(rddzavsioi) = fudsjwaufy luqbhoqxvz (fpmzwohrqj ) View more | - | 20 May 2009 |